Bill No. <u>CS for SB 2022</u>

	CHAMBER ACTION <u>Senate</u> <u>House</u>
-	
1	
2	
3 4	
4 5	
6	
7	
, 8	
9	
10	
11	The Committee on Judiciary (Saunders) recommended the
12	following amendment:
13	
14	Senate Amendment (with title amendment)
15	Delete everything after the enacting clause
16	
17	and insert:
18	Section 1. Subsection (13) of section 465.003, Florida
19	Statutes, is amended to read:
20	465.003 DefinitionsAs used in this chapter, the
21	term:
22	(13) "Practice of the profession of pharmacy" includes
23	compounding, dispensing, and consulting concerning contents,
24	therapeutic values, and uses of any medicinal drug; consulting
25	concerning therapeutic values and interactions of patent or
26	proprietary preparations, whether pursuant to prescriptions or
27	in the absence and entirely independent of such prescriptions
28	or orders; and other pharmaceutical services. For purposes of
29	this subsection, "other pharmaceutical services" means the
30	monitoring of the patient's drug therapy and assisting the
31	patient in the management of his or her drug therapy, and $1$
	11:15 AM 04/06/07 s2022cld-ju37-t01

COMMITTEE AMENDMENT

Bill No. <u>CS for SB 2022</u>

1	includes review of the patient's drug therapy and
2	communication with the patient's prescribing health care
3	provider as licensed under chapter 458, chapter 459, chapter
4	461, or chapter 466, or similar statutory provision in another
5	jurisdiction, or such provider's agent or such other persons
6	as specifically authorized by the patient, regarding the drug
7	therapy. However, nothing in this subsection may be
8	interpreted to permit an alteration of a prescriber's
9	directions, the diagnosis or treatment of any disease, the
10	initiation of any drug therapy, the practice of medicine, or
11	the practice of osteopathic medicine, unless otherwise
12	permitted by law. "Practice of the profession of pharmacy"
13	also includes any other act, service, operation, research, or
14	transaction incidental to, or forming a part of, any of the
15	foregoing acts, requiring, involving, or employing the science
16	or art of any branch of the pharmaceutical profession, study,
17	or training, and shall expressly permit a pharmacist to
18	transmit information from persons authorized to prescribe
19	medicinal drugs to their patients. The practice of the
20	profession of pharmacy also includes the administration of
21	influenza virus immunizations to adults pursuant to s.
22	<u>465.189.</u>
23	Section 2. Section 465.189, Florida Statutes, is
24	created to read:
25	465.189 Administration of influenza virus
26	immunizations
27	(1) Pharmacists may administer influenza virus
28	immunizations to adults within the framework of an established
29	protocol under a supervisory practitioner who is a physician
30	licensed under chapter 458 or chapter 459 or by written
31	agreement with a county health department. Each protocol shall
	11:15 AM 04/06/07 s2022cld-ju37-t01

COMMITTEE AMENDMENT

Bill No. CS for SB 2022

#### Barcode 350622

1 contain specific procedures for addressing any unforeseen allergic reaction to influenza virus immunizations. 2 (2) A pharmacist may not enter into a protocol unless 3 4 he or she maintains at least \$200,000 of professional liability insurance and has completed training in influenza 5 virus immunizations as provided in this section. 6 7 (3) A pharmacist administering influenza virus immunizations shall maintain and make available patient 8 records using the same standards for confidentiality and 9 10 maintenance of such records as those that are imposed on 11 health care practitioners under s. 456.057. These records shall be maintained for a minimum of 5 years. 12 (4) The decision by a supervisory practitioner to 13 enter into a protocol under this section is a professional 14 15 decision on the part of the practitioner and a person may not interfere with a supervisory practitioner's decision as to 16 entering into such a protocol. A pharmacist may not enter into 17 a protocol that is to be performed while acting as an employee 18 19 without the written approval of the owner of the pharmacy. Pharmacists shall forward immunization records to the 20 department for inclusion in the state registry of immunization 21 22 information. (5) Any pharmacist seeking to administer influenza 23 2.4 virus immunizations to adults under this section must be certified to administer influenza virus immunizations pursuant 25 to a certification program approved by the Board of Pharmacy. 2.6 The certification program shall, at a minimum, require that 27 the pharmacist attend at least 20 hours of continuing 28 education classes approved by the board. The program shall 29 have a curriculum of instruction concerning the safe and 30 31 effective administration of influenza virus immunizations, 3 11:15 AM 04/06/07 s2022c1d-ju37-t01

Bill No. <u>CS for SB 2022</u>

#### Barcode 350622

1 including, but not limited to, potential allergic reactions to 2 influenza virus immunizations. (6) The pharmacist shall submit to the Board of 3 4 Pharmacy a copy of his or her protocol or written agreement to 5 administer influenza virus immunizations. б Section 3. Task Force for the Study of Biotech 7 Competitiveness.--(1) INTENT.--8 9 (a) The Legislature finds that an estimated 20 10 diseases can be cured through immunizations and that immunizations provided early in a child's life, and as 11 scheduled during adolescence and adulthood, provide a strong 12 13 foundation of disease prevention and overall health. The Legislature further finds that every dollar spent on 14 15 immunization saves an average \$10 in future disease-related health care costs. The Legislature recognizes that 16 immunization education and disease-awareness programs lead to 17 18 improved vaccine usage and better health outcomes. The 19 Legislature further acknowledges that rapid immunization 20 distribution is an important factor in managing the containment of diseases under normal circumstances and is of 21 22 vital importance during mass outbreaks of diseases or natural 23 disasters. The Legislature further recognizes that the threat 2.4 of a bioterrorism, pandemic influenza, or other disaster of widespread proportion exists in our world today and that 25 access to vaccines and health care services are essential 2.6 27 combatants against these threats. (b) The Legislature finds that immunization 28 29 manufacturing and distribution is enhanced by siting vaccine manufacturing corporations in this state. The Legislature 30 31 recognizes that the state's efforts through existing biotech 4 11:15 AM 04/06/07 s2022c1d-ju37-t01

COMMITTEE AMENDMENT

Bill No. <u>CS for SB 2022</u>

1	research funded through various state research programs,
2	including the James and Esther King Biomedical Research
3	Program, the William G. "Bill" Bankhead, Jr., and David Coley
4	Cancer Research Program, the Johnnie B. Byrd Senior
5	Alzheimer's Center and Research Institute, the Scripps Florida
6	Funding Corporation, and the High Impact Performance Incentive
7	grants, which are directed toward developing and expanding the
8	state's biotech industry result in the expansion of biotech
9	research capacity and create biotech manufacturing and
10	distribution jobs in Florida. The Legislature further finds
11	that current and future collaboration among the state's
12	university researchers and private and public research efforts
13	creates a robust opportunity to encourage biotech research,
14	manufacturing, and the distribution of vaccines.
15	(c) It is the intent of the Legislature that this
16	state strive to become the nation's leader in immunizations
17	and commit itself to encouraging companies to locate to
18	Florida to help achieve this goal. Moreover, it is the intent
19	of the Legislature to expand the state's economy by attracting
20	biotech manufacturing companies to Florida.
21	(2) ESTABLISHMENT OF TASK FORCEThere is created
22	within the Governor's Office of Tourism, Trade, and Economic
23	Development the Task Force on the Study of Biotech
24	Competitiveness. The staff shall provide support for the task
25	force using internal staff or through a contracted consultant.
26	(3) MEMBERSHIP
27	(a) The task force shall consist of 17 members
28	appointed as follows:
29	1. The Governor shall appoint seven members: one
30	member from the Governor's Office of Tourism, Trade, and
31	Economic Development; the Secretary or Surgeon General of the
	5 11:15 AM 04/06/07 5 s2022cld-ju37-t01

COMMITTEE AMENDMENT

Bill No. <u>CS for SB 2022</u>

1	Department of Health or her designee; one member from the
2	Department of Education having expertise in workforce
3	education; one member from the Agency for Workforce Innovation
4	having expertise in workforce readiness; one member from the
5	Florida Research Consortium having training and experience in
6	technology transfer; one member representing the Medical
7	Device Manufacturing Association; and one member from
8	Enterprise Florida, Inc.
9	2. The Senate President shall appoint five members:
10	one member representing the Torrey Pines Research Institute;
11	one member representing the Burnham Research Institute; one
12	member representing an established biotech company that has
13	sited a manufacturing or distribution facility outside Florida
14	in the last 12 months; one member who is a site-selection
15	consultant who has worked with biotech companies in the
16	sighting of manufacturing and distribution facilities in
17	states outside Florida; and one member representing the
18	Florida Public Health Foundation, Inc.
19	3. The Speaker of the House of Representatives shall
20	appoint five members: one member representing the Scripps
21	Research Institute; one member representing BioFlorida; one
22	member representing the water management districts; one member
23	representing a local economic development authority; and one
24	member representing the Board of Governors of the State
25	University System.
26	(b) In making these appointments the Governor, the
27	President of the Senate, and the Speaker of the House of
28	Representatives shall select members who reflect the diversity
29	of the state's population. One member shall be designated by
30	the Governor as chair of the task force.
31	(c) Members of the task force shall serve without
	11:15 AM 04/06/07 s2022cld-ju37-t01

COMMITTEE AMENDMENT

Bill No. <u>CS for SB 2022</u>

1	compensation, but are entitled to reimbursement as provided in
2	s. 112.061, Florida Statutes, for travel and other necessary
3	expenses incurred in the performance of their official duties.
4	(4) PURPOSE
5	(a) The task force shall study economic policies
6	necessary for making Florida competitive with other states in
7	attracting and retaining a biotech manufacturing and
8	distribution workforce. The study shall include, but not be
9	limited to, the following review and analysis:
10	1. The state's corporate taxation system and its
11	effect on attracting biotech manufacturing and distribution
12	facilities to the state. This review includes, but is not be
13	limited to, implementing a single sales-factor formula to
14	apportion the corporate income of biotech businesses for tax
15	purposes;
16	2. The state's water policies and their effect on
17	meeting the water needs of the biotech manufacturing process;
18	3. The state's education and workforce training
19	programs and workforce preparedness for employment in the
20	biotech manufacturing and distribution fields;
21	4. The state's Medicaid program, state employee health
22	plans, and private health insurance policies and regulations
23	and the extent to which they provide support for products
24	generated by biotech companies; and
25	5. Other states' initiatives that have had success in
26	attracting and retaining biotech manufacturing and
27	distribution facilities and an evaluation of Florida's
28	readiness to compete with other states.
29	(b) The study shall provide recommendations concerning
30	maximizing federal revenues to the state.
31	(c) The study shall provide recommendations concerning
	11:15 AM 04/06/07 / s2022cld-ju37-t01
	I

COMMITTEE AMENDMENT

Bill No. <u>CS for SB 2022</u>

1	how this state's existing policies and programs can be
2	modified to ensure competitiveness when evaluated by companies
3	making siting decisions related to biotech manufacturing and
4	distribution facilities.
5	(5) REPORTThe task force shall report the findings
6	of the study to the Governor, the President of the Senate, and
7	the Speaker of the House of Representatives by January 1,
8	<u>2009.</u>
9	(6) EXPIRATIONThe task force is dissolved June 30,
10	<u>2009.</u>
11	Section 4. This act shall take effect July 1, 2007.
12	
13	
14	========= TITLE AMENDMENT==========
15	And the title is amended as follows:
16	Delete everything before the enacting clause
17	
18	and insert:
19	A bill to be entitled
20	An act relating to immunization services;
21	amending s. 465.003, F.S.; revising a
22	definition relating to the practice of
23	pharmacists; creating s. 465.189, F.S.;
24	authorizing pharmacists to administer influenza
25	virus immunizations to adults; providing
26	requirements with respect thereto; creating the
27	Task Force for the Study of Biotech
28	Competitiveness; providing for staff support by
29	the Governor's Office of Tourism, Trade, and
30	Economic Development; providing for appointment
31	of members; requiring a study; requiring a
	8 11:15 AM 04/06/07 s2022cld-ju37-t01

COMMITTEE AMENDMENT

Bill No. <u>CS for SB 2022</u>

1	report; providing for expiration of the task	
2	force; providing an effective date.	
3		
4		
5		
б		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		
31	9	
	11:15 AM 04/06/07 s2022cld-ju37-t01	